MX2023000303A - Coagonistas de los receptores del peptido 1 similar al glucagon (glp-1) y del polipeptido insulinotropico dependiente de glucosa (gip) adecuados para el suministro oral. - Google Patents

Coagonistas de los receptores del peptido 1 similar al glucagon (glp-1) y del polipeptido insulinotropico dependiente de glucosa (gip) adecuados para el suministro oral.

Info

Publication number
MX2023000303A
MX2023000303A MX2023000303A MX2023000303A MX2023000303A MX 2023000303 A MX2023000303 A MX 2023000303A MX 2023000303 A MX2023000303 A MX 2023000303A MX 2023000303 A MX2023000303 A MX 2023000303A MX 2023000303 A MX2023000303 A MX 2023000303A
Authority
MX
Mexico
Prior art keywords
agonists
oral delivery
glp
gip receptors
receptors suitable
Prior art date
Application number
MX2023000303A
Other languages
English (en)
Inventor
Brian Finan
Lars Linderoth
Patrick J Knerr
Richard Dimarchi
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of MX2023000303A publication Critical patent/MX2023000303A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se describen coagonistas peptídicos de los receptores de GLP-1 y GIP humanos adecuados para el suministro oral, que incluyen derivados de acción prolongada, y su uso médico en el tratamiento y/o la prevención de la obesidad, la diabetes y/o enfermedades hepáticas.
MX2023000303A 2020-07-22 2021-07-22 Coagonistas de los receptores del peptido 1 similar al glucagon (glp-1) y del polipeptido insulinotropico dependiente de glucosa (gip) adecuados para el suministro oral. MX2023000303A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063055026P 2020-07-22 2020-07-22
EP20192414 2020-08-24
US202163156988P 2021-03-05 2021-03-05
PCT/EP2021/070485 WO2022018186A1 (en) 2020-07-22 2021-07-22 Co-agonists at glp-1 and gip receptors suitable for oral delivery

Publications (1)

Publication Number Publication Date
MX2023000303A true MX2023000303A (es) 2023-02-09

Family

ID=77179985

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023000303A MX2023000303A (es) 2020-07-22 2021-07-22 Coagonistas de los receptores del peptido 1 similar al glucagon (glp-1) y del polipeptido insulinotropico dependiente de glucosa (gip) adecuados para el suministro oral.

Country Status (14)

Country Link
US (4) US20220177538A1 (es)
EP (1) EP4185607A1 (es)
JP (1) JP2023534131A (es)
KR (2) KR102446310B1 (es)
CN (1) CN116157143A (es)
AU (1) AU2021312323A1 (es)
BR (1) BR112023000270A2 (es)
CA (1) CA3184717A1 (es)
CL (1) CL2023000087A1 (es)
CO (1) CO2023000097A2 (es)
IL (1) IL299701A (es)
MX (1) MX2023000303A (es)
TW (2) TW202315883A (es)
WO (1) WO2022018186A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4185607A1 (en) 2020-07-22 2023-05-31 Novo Nordisk A/S Co-agonists at glp-1 and gip receptors suitable for oral delivery
WO2023012263A1 (en) 2021-08-04 2023-02-09 Novo Nordisk A/S Solid oral peptide formulations
TW202330584A (zh) 2022-01-20 2023-08-01 丹麥商諾佛 儂迪克股份有限公司 前藥及其用途
CN117402219A (zh) * 2022-07-13 2024-01-16 杭州中美华东制药有限公司 Glp-1/gip双激动剂及其制备方法和用途

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2300035T3 (pl) 2008-06-17 2016-04-29 Univ Indiana Res & Tech Corp Mieszani agoniści na bazie GIP do leczenia zaburzeń metabolicznych i otyłości
KR20110110174A (ko) 2008-12-19 2011-10-06 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 아미드 기반 글루카곤 슈퍼패밀리 펩티드 프로드럭
CA2747195A1 (en) 2008-12-19 2010-07-15 Indiana University Research And Technology Corporation Dipeptide linked medicinal agents
MX2011013625A (es) 2009-06-16 2012-01-20 Univ Indiana Res & Tech Corp Compuestos glucagon activo de receptor de gip.
WO2011080102A2 (en) 2009-12-16 2011-07-07 Novo Nordisk A/S Glp-1 analogues and derivatives
CA2796894A1 (en) 2010-06-24 2011-12-29 Indiana University Research And Technology Corporation Amide based glucagon superfamily peptide prodrugs
JP6101202B2 (ja) 2010-06-24 2017-03-22 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ ジペプチド結合医薬剤
RU2600440C3 (ru) 2010-12-16 2021-12-10 Ново Нордиск А/С Твердые композиции, содержащие агонист glp-1 и соль n-(8-(2-гидроксибензоил)амино)каприловой кислоты
MA34885B1 (fr) 2010-12-22 2014-02-01 Indiana Unversity Res And Technology Corp Analogues du glucagon presentant una ctivite de recepteur de gip
AR084558A1 (es) * 2010-12-22 2013-05-22 Marcadia Biotech Metodos para tratar trastornos metabolicos y obesidad con peptidos basados en glucagon activos para el receptor de peptido insulinotropico dependiente de glucosa (gip)/peptido-1 similar al glucagon (glp-1)
WO2012167744A1 (en) 2011-06-10 2012-12-13 Beijing Hanmi Pharmaceutical Co., Ltd. Glucose dependent insulinotropic polypeptide analogs, pharmaceutical compositions and use thereof
HRP20231613T1 (hr) * 2012-03-22 2024-03-15 Novo Nordisk A/S Pripravci koji sadrže sredstvo za unošenje i njihova priprava
IN2014MN02304A (es) 2012-05-03 2015-08-07 Zealand Pharma As
EP2863895B1 (en) 2012-06-20 2021-04-14 Novo Nordisk A/S Tablet formulation comprising a peptide and a delivery agent
AR091478A1 (es) 2012-06-21 2015-02-04 Univ Indiana Res & Tech Corp Analogos de glucagon que exhiben actividad de receptor de gip (peptido insulinotropico dependiente de glucosa)
ES2688367T3 (es) 2012-12-21 2018-11-02 Sanofi Derivados de exendina-4 como agonistas duales de GLP1/GIP o trigonales de GLP1/GIP/glucagón
US20160058881A1 (en) 2013-03-15 2016-03-03 Indiana University Research And Technology Corporation Prodrugs with prolonged action
BR112015026325A2 (pt) * 2013-05-02 2017-07-25 Novo Nordisk As dosagem oral de compostos glp-1
TWI638831B (zh) 2013-05-28 2018-10-21 日商武田藥品工業股份有限公司 胜肽化合物
EP3033355A1 (en) 2013-08-16 2016-06-22 Medimmune Limited Gip and glp-1 receptor dual-agonists for the treatment of diabetes
WO2015035419A1 (en) 2013-09-09 2015-03-12 Hoffmann-La Roche Inc. Dosages of gip/glp-1 co-agonist peptides for human administration
CA2929459C (en) * 2013-11-06 2022-05-03 Zealand Pharma A/S Gip-glp-1 dual agonist compounds and methods
TW201609795A (zh) 2013-12-13 2016-03-16 賽諾菲公司 作為雙重ｇｌｐ－１／ｇｉｐ受體促效劑的艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
EP3080154B1 (en) 2013-12-13 2018-02-07 Sanofi Dual glp-1/gip receptor agonists
TW201625670A (zh) * 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
GB2528436A (en) 2014-07-15 2016-01-27 Lancaster Univ Business Entpr Ltd Treatment of neurological diseases
EP3197912B1 (en) 2014-09-24 2023-01-04 Indiana University Research & Technology Corporation Lipidated amide-based insulin prodrugs
WO2016077220A1 (en) 2014-11-10 2016-05-19 Mb2 Llc Gip/glp-1 co-agonist peptides for human administration
JP2018012644A (ja) 2014-11-26 2018-01-25 武田薬品工業株式会社 ペプチド化合物
JOP20200119A1 (ar) 2015-01-09 2017-06-16 Lilly Co Eli مركبات مساعد مشترك من gip وglp-1
WO2016131893A1 (en) 2015-02-18 2016-08-25 Medimmune Limited Incretin fusion polypeptides
US20170112897A1 (en) 2015-10-23 2017-04-27 Cedars-Sinai Medical Center Methods for treating brain insulin resistance
WO2017204219A1 (ja) 2016-05-24 2017-11-30 武田薬品工業株式会社 ペプチド化合物
GB201620611D0 (en) 2016-12-05 2017-01-18 Univ Of Lancaster Treatment of neurological diseases
JOP20180028A1 (ar) 2017-03-31 2019-01-30 Takeda Pharmaceuticals Co مركب ببتيد
EP3746111B1 (en) 2018-02-02 2023-07-19 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant
CN112074531A (zh) 2018-05-04 2020-12-11 诺和诺德股份有限公司 Gip衍生物及其用途
WO2020023382A1 (en) 2018-07-23 2020-01-30 Eli Lilly And Company Methods of using a gip/glp1 co-agonist for therapy
EP3827015A1 (en) 2018-07-23 2021-06-02 Eli Lilly and Company Gip/glp1 co-agonist compounds
IL280159B1 (en) 2018-07-23 2024-01-01 Lilly Co Eli Methods of using a GIP/GLP1 co-agonist for diabetes
BR112021020071A2 (pt) * 2019-04-11 2021-12-14 Jiangsu Hansoh Pharmaceutical Group Co Ltd Compostos agonistas duplos do receptor de glp-1 e gip e uso dos mesmos
CN110642935A (zh) 2019-09-25 2020-01-03 成都奥达生物科技有限公司 一种替瑞帕肽类似物
CN110684082B (zh) 2019-10-08 2021-12-10 江苏诺泰澳赛诺生物制药股份有限公司 Gip和glp-1双激动多肽化合物及药学上可接受的盐与用途
EP4185607A1 (en) 2020-07-22 2023-05-31 Novo Nordisk A/S Co-agonists at glp-1 and gip receptors suitable for oral delivery

Also Published As

Publication number Publication date
CL2023000087A1 (es) 2023-07-07
CN116157143A (zh) 2023-05-23
US20220125940A1 (en) 2022-04-28
JP2023534131A (ja) 2023-08-08
US20230272029A1 (en) 2023-08-31
KR102446310B1 (ko) 2022-09-23
BR112023000270A2 (pt) 2023-01-31
TWI801942B (zh) 2023-05-11
WO2022018186A1 (en) 2022-01-27
KR20230029480A (ko) 2023-03-03
TW202315883A (zh) 2023-04-16
US11779648B2 (en) 2023-10-10
AU2021312323A1 (en) 2023-02-02
TW202208411A (zh) 2022-03-01
EP4185607A1 (en) 2023-05-31
IL299701A (en) 2023-03-01
CO2023000097A2 (es) 2023-03-27
US20220177538A1 (en) 2022-06-09
CA3184717A1 (en) 2022-01-27
US20230120597A1 (en) 2023-04-20
KR20220012840A (ko) 2022-02-04

Similar Documents

Publication Publication Date Title
MX2023000303A (es) Coagonistas de los receptores del peptido 1 similar al glucagon (glp-1) y del polipeptido insulinotropico dependiente de glucosa (gip) adecuados para el suministro oral.
CY1116727T1 (el) Θεραπεια πολλαπλης σκληρυνσης me laquinimod
DK1173178T3 (da) Præparat, der omfatter apomorfin og sildenafil, og anvendelse deraf til behandling af erektil dysfunktion
CR20230330A (es) Agonistas del receptor gpcr, composiciones farmaceuticas que los comprenden y métodos para su uso
TW200616608A (en) Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients
UA94734C2 (ru) ТЕРАПЕВТИЧЕСКОЕ АНТИТЕЛО, КОТОРОЕ СВЯЗЫВАЕТСЯ С b-АМИЛОИДНЫМ ПЕПТИДОМ
CY1112184T1 (el) Πυριδοξαμινη για χρηση στην αγωγη της διαβητικης nεφροπαθειας στο διαβητη τυπου ii
UA106756C2 (uk) Генетичні маркери, асоційовані з відповіддю на інтерферон-альфа
MX2018010640A (es) Co-agonistas del glucagon y de glp-1 para el tratamiento de la obesidad.
IL175259A0 (en) Use of a deoxynojirimycin derivative or a pharmaceutically salt thereof
CA2632207C (en) Use of calcitonin for the treatment of ra
EP1543158A4 (en) REGULATED APTAMER THERAPEUTICS
MX2008002456A (es) Uso de ambroxol para el tratamiento de infecciones por rinovirus.
AU2021391241B2 (en) Lactam-modified polypeptide compounds
MX2023000403A (es) Coagonistas de los receptores del peptido 1 similar al glucagon (glp-1) y del peptido insulinotropico dependiente de glucosa (gip).
MX341660B (es) Agonista del receptor de ghrelina para el tratamiento de caquexia.
MX2019014687A (es) Formulaciones farmaceuticas orales de remogliflozina.
TW200511999A (en) Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and parathyroid hormone
CL2023000296A1 (es) Uso de dexpramipexol para el tratamiento del asma moderado a grave
MX2009006670A (es) Composicion farmaceutica que usa el aliskiren y el avosentan.
MX2022003628A (es) Regímenes de dosificación para el tratamiento de pacientes con carcinoma de células escamosas avanzado localmente.
MX2021007324A (es) Terapia oral con acido 6,8-bis-benciltio-octanoico.
JOP20170044B1 (ar) تركيبة صيدلانية تشتمل على hgh ناتج عن عودة الارتباط الجيني لعلاج نقص هرمون النمو
EA202090416A1 (ru) Способы лечения симптомов гастропареза с использованием велусетрага
AR109456A2 (es) Uso de et743 para la preparación de un medicamento para el tratamiento de un paciente humano afectado por cáncer mediante terapia de combinación